282 related articles for article (PubMed ID: 24905725)
1. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study.
Hirata T; Izumi G; Takamura M; Saito A; Nakazawa A; Harada M; Hirota Y; Koga K; Fujii T; Osuga Y
Gynecol Endocrinol; 2014 Oct; 30(10):726-9. PubMed ID: 24905725
[TBL] [Abstract][Full Text] [Related]
2. Long-term dienogest administration in patients with symptomatic adenomyosis.
Neriishi K; Hirata T; Fukuda S; Izumi G; Nakazawa A; Yamamoto N; Harada M; Hirota Y; Koga K; Wada-Hiraike O; Fujii T; Osuga Y
J Obstet Gynaecol Res; 2018 Aug; 44(8):1439-1444. PubMed ID: 29845696
[TBL] [Abstract][Full Text] [Related]
3. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis.
Osuga Y; Watanabe M; Hagino A
J Obstet Gynaecol Res; 2017 Sep; 43(9):1441-1448. PubMed ID: 28737239
[TBL] [Abstract][Full Text] [Related]
4. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis.
Ota K; Takahashi T; Shiraishi S; Mizunuma H
J Obstet Gynaecol Res; 2018 Sep; 44(9):1787-1792. PubMed ID: 29998482
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.
Fawzy M; Mesbah Y
Arch Gynecol Obstet; 2015 Dec; 292(6):1267-71. PubMed ID: 25990480
[TBL] [Abstract][Full Text] [Related]
6. Expression of Lewis (b) blood group antigen interferes with oral dienogest therapy among women with adenomyosis.
Xue J; Li L; Li F; Li N; Li T; Li C
J Reprod Immunol; 2020 Feb; 137():103079. PubMed ID: 31927399
[TBL] [Abstract][Full Text] [Related]
7. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study.
Grandi G; Xholli A; Napolitano A; Palma F; Cagnacci A
Reprod Sci; 2015 May; 22(5):626-32. PubMed ID: 25394646
[TBL] [Abstract][Full Text] [Related]
8. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis.
Takeuchi A; Koga K; Miyashita M; Makabe T; Sue F; Harada M; Hirata T; Hirota Y; Fujii T; Osuga Y
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():157-161. PubMed ID: 27865118
[TBL] [Abstract][Full Text] [Related]
9. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study.
Strowitzki T; Faustmann T; Gerlinger C; Seitz C
Eur J Obstet Gynecol Reprod Biol; 2010 Aug; 151(2):193-8. PubMed ID: 20444534
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.
Hassanin AI; Youssef AA; Yousef AM; Ali MK
Int J Gynaecol Obstet; 2021 Aug; 154(2):263-269. PubMed ID: 33454995
[TBL] [Abstract][Full Text] [Related]
11. [Behavior of parameters of liver metabolism in intermediate-term use of the gestagen dienogest in the treatment of endometriosis].
Köhler G; Lembke S; Brachmann K; Foth D; Happke S
Zentralbl Gynakol; 1989; 111(12):807-10. PubMed ID: 2763750
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of endometriosis with dienogest].
Köhler G; Göretzlehner G; Amon I
Zentralbl Gynakol; 1987; 109(12):795-801. PubMed ID: 3630463
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
Osuga Y; Fujimoto-Okabe H; Hagino A
Fertil Steril; 2017 Oct; 108(4):673-678. PubMed ID: 28911934
[TBL] [Abstract][Full Text] [Related]
14. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest.
Nagata C; Yanagida S; Okamoto A; Morikawa A; Sugimoto K; Okamoto S; Ochiai K; Tanaka T
J Obstet Gynaecol Res; 2012 Apr; 38(4):639-44. PubMed ID: 22413833
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
[TBL] [Abstract][Full Text] [Related]
16. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
[TBL] [Abstract][Full Text] [Related]
17. High-dose pilot study with the novel progestogen dienogestin patients with endometriosis.
Schindler AE; Christensen B; Henkel A; Oettel M; Moore C
Gynecol Endocrinol; 2006 Jan; 22(1):9-17. PubMed ID: 16522528
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
Miao J; Lu J; Tang J; Lu P
Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
[No Abstract] [Full Text] [Related]
19. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
Matsushima T; Akira S; Yoneyama K; Takeshita T
Gynecol Endocrinol; 2020 Jun; 36(6):521-524. PubMed ID: 31661345
[TBL] [Abstract][Full Text] [Related]
20. Use of dienogest over 53 weeks for the treatment of endometriosis.
Sugimoto K; Nagata C; Hayashi H; Yanagida S; Okamoto A
J Obstet Gynaecol Res; 2015 Dec; 41(12):1921-6. PubMed ID: 26369271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]